352 related articles for article (PubMed ID: 11719835)
1. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial.
Jude EB; Selby PL; Burgess J; Lilleystone P; Mawer EB; Page SR; Donohoe M; Foster AV; Edmonds ME; Boulton AJ
Diabetologia; 2001 Nov; 44(11):2032-7. PubMed ID: 11719835
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy?
Selby PL; Young MJ; Boulton AJ
Diabet Med; 1994; 11(1):28-31. PubMed ID: 8181248
[TBL] [Abstract][Full Text] [Related]
3. Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic diabetic Charcot neuroarthropathy.
Gough A; Abraha H; Li F; Purewal TS; Foster AV; Watkins PJ; Moniz C; Edmonds ME
Diabet Med; 1997 Jul; 14(7):527-31. PubMed ID: 9223389
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates for the treatment of Charcot neuroarthropathy.
Anderson JJ; Woelffer KE; Holtzman JJ; Jacobs AM
J Foot Ankle Surg; 2004; 43(5):285-9. PubMed ID: 15480402
[TBL] [Abstract][Full Text] [Related]
5. Calcaneal bone mineral density in patients with Charcot neuropathic osteoarthropathy: differences between Type 1 and Type 2 diabetes.
Petrova NL; Foster AV; Edmonds ME
Diabet Med; 2005 Jun; 22(6):756-61. PubMed ID: 15910628
[TBL] [Abstract][Full Text] [Related]
6. The diabetic Charcot foot.
Dissanayake SU; Bowling FL; Jude EB
Curr Diabetes Rev; 2012 May; 8(3):191-4. PubMed ID: 22429012
[TBL] [Abstract][Full Text] [Related]
7. Osteoprotegerin gene polymorphism in diabetic Charcot neuroarthropathy.
Korzon-Burakowska A; Jakóbkiewicz-Banecka J; Fiedosiuk A; Petrova N; Koblik T; Gabig-Cimińska M; Edmonds M; Małecki MT; Węgrzyn G
Diabet Med; 2012 Jun; 29(6):771-5. PubMed ID: 21913967
[TBL] [Abstract][Full Text] [Related]
8. Asymmetrical attenuation of vibration sensation in unilateral diabetic Charcot foot neuroarthropathy.
Valabhji J; Marshall RC; Lyons S; Bloomfield L; Hogg D; Rosenfeld P; Gabriel CM
Diabet Med; 2012 Sep; 29(9):1191-4. PubMed ID: 22276944
[TBL] [Abstract][Full Text] [Related]
9. Aspirin compared with acetaminophen in the treatment of fever and other symptoms of upper respiratory tract infection in adults: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-dose, 6-hour dose-ranging study.
Bachert C; Chuchalin AG; Eisebitt R; Netayzhenko VZ; Voelker M
Clin Ther; 2005 Jul; 27(7):993-1003. PubMed ID: 16154478
[TBL] [Abstract][Full Text] [Related]
10. Diabetes and acute Charcot neuroarthropathy--a call for heightened vigilance.
Iheonunekwu N; Ibrahim TM; Ojuro I
Niger J Med; 2010; 19(2):239-40. PubMed ID: 20642098
[No Abstract] [Full Text] [Related]
11. The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy: a pilot randomized controlled trial.
Pakarinen TK; Laine HJ; Mäenpää H; Mattila P; Lahtela J
Diabetes Care; 2011 Jul; 34(7):1514-6. PubMed ID: 21593295
[TBL] [Abstract][Full Text] [Related]
12. Recurrence of the acute Charcot foot in diabetes.
Rudrappa S; Game F; Jeffcoate W
Diabet Med; 2012 Jun; 29(6):819-21. PubMed ID: 22587408
[TBL] [Abstract][Full Text] [Related]
13. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
Vinik AI; Bril V; Kempler P; Litchy WJ; Tesfaye S; Price KL; Bastyr EJ;
Clin Ther; 2005 Aug; 27(8):1164-80. PubMed ID: 16199243
[TBL] [Abstract][Full Text] [Related]
14. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy.
Ekberg K; Brismar T; Johansson BL; Lindström P; Juntti-Berggren L; Norrby A; Berne C; Arnqvist HJ; Bolinder J; Wahren J
Diabetes Care; 2007 Jan; 30(1):71-6. PubMed ID: 17192336
[TBL] [Abstract][Full Text] [Related]
15. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis.
Maksymowych WP; Jhangri GS; Fitzgerald AA; LeClercq S; Chiu P; Yan A; Skeith KJ; Aaron SL; Homik J; Davis P; Sholter D; Russell AS
Arthritis Rheum; 2002 Mar; 46(3):766-73. PubMed ID: 11920413
[TBL] [Abstract][Full Text] [Related]
16. Risk factors of charcot neuroarthropathy development in patients with type 2 diabetes.
Nehring P; Mrozikiewicz-Rakowska B; Maroszek P; Sobczyk-Kopcioł A; Krzyżewska M; Płoski R; Karnafel W
Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):31-4. PubMed ID: 24203651
[TBL] [Abstract][Full Text] [Related]
17. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
Rogers A; Glover SJ; Eastell R
Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
[TBL] [Abstract][Full Text] [Related]
18. Long-term foot outcomes following differential abatement of inflammation and osteoclastogenesis for active Charcot neuroarthropathy in diabetes mellitus.
Das L; Rastogi A; Jude EB; Prakash M; Dutta P; Bhansali A
PLoS One; 2021; 16(11):e0259224. PubMed ID: 34748565
[TBL] [Abstract][Full Text] [Related]
19. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
[TBL] [Abstract][Full Text] [Related]
20. Bone mineral density and markers of bone turnover and inflammation in diabetes patients with or without a Charcot foot: An 8.5-year prospective case-control study.
Jansen RB; Christensen TM; Bülow J; Rørdam L; Holstein PE; Jørgensen NR; Svendsen OL
J Diabetes Complications; 2018 Feb; 32(2):164-170. PubMed ID: 29196119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
